Nuvation Bio is trading 4.18% down now at $5.84 as broader equity weakness pressures risk-sensitive stocks.
- U.S. indices are lower on September 23, 2026, amid renewed inflation concerns, higher crude oil prices and a 4.99% 10-year Treasury yield.
- The latest company-specific catalyst was the September 16 FDA approval of an updated IBTROZI label; no new Nuvation Bio announcement explains today’s decline.